Pluri Inc. — SEC Form D Filing
Pluri Inc. filed an SEC Form D on September 4, 2026, reporting $3.68M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 4, 2026
- Amount reported
- $3.68M
- Round stage
- Series A because a $3.6 million raise represents an early-stage institutional round typical for advancing preclinical biotech assets toward clinical trials.
- Industry
- Biotechnology
- Website
- https://pluri-biotech.com
What the company does
Exemption: Rule 506(b). Incorporated: NEVADA
Problem
Developing scalable, consistent, and high-quality pluripotent stem cell therapies is hindered by complex manufacturing processes and high production costs.
Solution
Pluri designs and manufactures standardized, clinical-grade pluripotent stem cell platforms to accelerate the development of regenerative medicine therapies.
Why now
Recent regulatory advancements in cell therapy approvals and breakthroughs in CRISPR-based gene editing have surged the demand for reliable, off-the-shelf cellular starting materials.
Source: SEC EDGAR Form D filing